- Home
- Results news
- Hemo Organic
- Q2 FY27 results
Hemo Organic Q2 FY27 results: net profit ₹0.01 crore vs ₹0.03 crore loss
Hemo Organic Ltd reported standalone revenue of ₹1.43 crore and a net profit of ₹0.01 crore for Q2 FY27, compared with ₹0 crore revenue and a net loss of ₹0.03 crore in Q2 FY26. The result also improved from Q1 FY27, when the company reported revenue of ₹0 crore and a net loss of ₹0.07 crore. Consolidated results are not applicable because the company has no associates, subsidiaries or joint ventures.
Key points
- Q2 FY27 revenue was ₹1.43 crore, against ₹0 crore in Q2 FY26 and ₹0 crore in Q1 FY27.
- EBITDA was ₹0.01 crore in Q2 FY27, compared with ₹0.04 crore of loss in Q2 FY26 and ₹0.07 crore of loss in Q1 FY27.
- Q2 FY27 net profit was ₹0.01 crore, with basic EPS of ₹0.01, against a net loss of ₹0.03 crore in Q2 FY26.
- H1 FY27 revenue was ₹1.43 crore and net profit was ₹0.01 crore, compared with ₹0 crore revenue and a net loss of ₹0.12 crore in H1 FY26.
- At 30 September 2026, total assets were ₹4.76 crore, total equity was ₹3.25 crore and borrowings were ₹1.29 crore.
How did Hemo Organic perform in Q2 FY27?
Hemo Organic reported standalone revenue of ₹1.43 crore in Q2 FY27, up ₹1.43 crore from ₹0 crore in Q2 FY26 and Q1 FY27. EBITDA turned to ₹0.01 crore from a loss of ₹0.04 crore a year earlier and a loss of ₹0.07 crore in the previous quarter. The EBITDA margin was 0.4%, compared with -41000.0% in Q2 FY26.
Profit before tax and net profit were ₹0.01 crore each in Q2 FY27, compared with losses of ₹0.04 crore and ₹0.03 crore, respectively, in Q2 FY26. Against Q1 FY27, both moved to profit from ₹0.07 crore losses, an improvement of ₹0.08 crore. Basic EPS was ₹0.01, against ₹0.21 of loss in Q1 FY27, an improvement of ₹0.22. The filing states that consolidated results are not applicable because there are no associates, subsidiaries or joint ventures.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.43 | 0 | 0 | ||
| Other income | 0 | 0 | 0 | ||
| Total expenses | 1.42 | 0.07 | 0.04 | +3450.0% | +1928.6% |
| EBITDA | 0.01 | −0.07 | −0.04 | turned to profit | turned to profit |
| EBITDA margin | 0.4% | -41000.0% | +41000.4 pp | ||
| Profit before tax | 0.01 | −0.07 | −0.04 | turned to profit | turned to profit |
| Tax | 0 | 0 | −0.01 | ||
| Net profit | 0.01 | −0.07 | −0.03 | turned to profit | turned to profit |
| EPS (₹) | 0.01 | −0.21 | turned to profit |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Hemo Organic's costs and profit?
Total expenses were ₹1.42 crore in Q2 FY27, up ₹1.38 crore from ₹0.04 crore in Q2 FY26 and ₹1.35 crore from ₹0.07 crore in Q1 FY27. Employee cost was unchanged from Q2 FY26 at ₹0.02 crore but rose ₹0.01 crore from Q1 FY27. Cost of materials, finance costs and depreciation were unchanged from both comparison periods.
Other expenses fell ₹0.02 crore, or 66.7%, from ₹0.03 crore in Q2 FY26 to ₹0.01 crore in Q2 FY27. They also fell ₹0.05 crore, or 83.3%, from ₹0.06 crore in Q1 FY27. Other income was unchanged from both periods, and there was no exceptional item. Tax moved up ₹0.01 crore from the year-ago quarter and was unchanged from Q1 FY27.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 0 | 0 | 0 | |
| Employee cost | 0.02 | 0.02 | 0 | +0.0% |
| Finance costs | 0 | 0 | 0 | |
| Depreciation | 0 | 0 | 0 | |
| Other expenses | 0.01 | 0.03 | −0.02 | −66.7% |
| Total expenses | 1.42 | 0.04 | +1.38 | +3450.0% |
| Other income | 0 | 0 | 0 | |
| Tax | 0 | −0.01 | +0.01 |
Source: Company's results filing (XBRL).
How did the first half of FY27 go?
In H1 FY27, Hemo Organic reported revenue and total income of ₹1.43 crore, against ₹0 crore in H1 FY26. Profit before tax was ₹0.07 crore of loss, compared with ₹0.16 crore of loss in H1 FY26, while net profit was ₹0.07 crore of loss, compared with ₹0.12 crore of loss. Basic EPS was ₹0.19 of loss in H1 FY27.
| ₹ crore | H1 FY27 | H1 FY26 | Change |
|---|---|---|---|
| Revenue from operations | 1.43 | 0 | |
| Profit before tax | −0.07 | −0.16 | |
| Net profit | −0.07 | −0.12 | |
| EPS (₹) | −0.19 |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
At 30 September 2026, total assets were ₹4.76 crore, compared with ₹4.46 crore at 31 March 2026. Total equity was ₹3.25 crore against ₹0.13 crore, while borrowings fell from ₹4.3 crore to ₹1.29 crore. Cash was ₹0.01 crore on both dates; inventories were ₹0.51 crore, trade receivables were ₹2.36 crore and trade payables were ₹0.19 crore.
H1 FY27 operating cash flow was an outflow of ₹1.83 crore, compared with an outflow of ₹0.17 crore in H1 FY26. Investing cash flow was an inflow of ₹0.09 crore against an outflow of ₹0 crore, and financing cash flow was an inflow of ₹1.74 crore against ₹0.16 crore.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 4.76 | 4.46 |
| Total equity | 3.25 | 0.13 |
| Borrowings | 1.29 | 4.30 |
| Cash and equivalents | 0.01 | 0.01 |
| Inventories | 0.51 | 0.51 |
| Trade receivables | 2.36 | 2.39 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 | H1 FY26 |
|---|---|---|
| Cash from operations | −1.83 | −0.17 |
| Cash from investing | 0.09 | 0 |
| Cash from financing | 1.74 | 0.16 |
| Capital expenditure | 0 | 0 |
Source: Company's results filing (XBRL).
How has Hemo Organic done over the last 8 quarters?
Revenue reached its highest reported quarterly level of ₹2.41 crore in Q4 FY25 and its lowest reported level of ₹0 crore in several quarters. It was ₹0.93 crore in Q4 FY26 and ₹1.43 crore in Q2 FY27, following ₹0 crore in Q1 FY27. Net profit was lowest at ₹0.51 crore of loss in Q4 FY26 and turned to ₹0.01 crore of profit in Q2 FY27. The EBITDA margin improved from -32.0% in Q4 FY26 to 0.4% in Q2 FY27.
What did the auditors point out?
The statutory auditor’s review report states that a review is substantially less in scope than an audit and does not enable the auditor to obtain assurance that all significant matters would become apparent. It says that, except as specified in the “Qualified Opinion” paragraph, nothing came to the auditor’s attention that caused belief that the unaudited financial results had not disclosed the information required under the applicable disclosure regulations or contained any material misstatement.
How did other Trading & Distributors companies do?
Among 24 other Trading & Distributors companies that had filed for the quarter as of 4 November 2026, the median revenue growth was 31.0%. Hemo Organic’s revenue growth was higher than that of peers growing more slowly and lower than that of peers growing faster; the filing does not provide the corresponding counts. Of the 36 peers for which profit was compared, 20 reported higher profit.
| Hemo Organic revenue growth (YoY) | not comparable |
|---|---|
| Median of 24 other Trading & Distributors companies | +31.0% |
| Companies whose net profit rose | 20 of 36 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Hemo Organic's revenue in Q2 FY27?
Revenue from operations was ₹1.43 crore, against ₹0 crore in Q2 FY26 (standalone).
Did Hemo Organic make a profit in Q2 FY27?
Yes. Net profit was ₹0.01 crore, against a net loss of ₹0.03 crore in Q2 FY26.
What was Hemo Organic's EPS in Q2 FY27?
Basic earnings per share were ₹0.01.
When did Hemo Organic announce its Q2 FY27 results?
On 17 October 2026, in a filing to the BSE.
Sources
- Board Meeting Outcome for The Meeting Held Today I.E., Saturday, 17Th October, 2026 (BSE, 17 October 2026) · PDF
- Submission Of Un-Audited Financial Results Along With Limited Review Report Thereon For The Quarter And Half Year Ended 30Th September, 2026 (BSE, 17 October 2026) · PDF
- Statement On Deviation(S) / Variation(S) In Utilization Of Proceeds Raised Through Preferential Issue Of Convertible Warrants, Pursuant To Regulation 32 Of SEBI (LODR) Regulations, 2015 ('SEBI Listing Regulations) For The Quarter Ended On September 30, 2026 (BSE, 17 October 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.